Memo Therapeutics is a late-stage biotech company based in Schlieren, Zurich, developing therapeutic antibodies for viral infections and cancer. Its lead program, AntiBKV, is a neutralizing antibody aimed at treating BK virus infection in kidney transplant recipients. The company holds FDA fast track status for AntiBKV and intends to use new funds to accelerate clinical development. Memo plans to expand its Phase II trial with a dose-evaluation extension supported by the financing. Its pipeline includes additional antibody candidates targeting infectious diseases such as cytomegalovirus (CMV) and immuno-oncology programs, including a partnership with Ono Pharmaceutical. The company is led by CEO Erik van den Berg. Memo Therapeutics AG (MTx) is a late-stage biotech based in Schlieren/Zurich, Switzerland, focused on developing best-in-class therapeutic antibodies for viral infections and cancer. Its lead program, AntiBKV, is a highly effective neutralizing antibody designed to treat BK polyomavirus infection in kidney transplant recipients, a condition that can lead to graft dysfunction and organ rejection. MTx plans to complete a multi-center U.S. Phase II study of AntiBKV and is preparing to scale up CMC manufacturing for a Phase III study and potential market entry. The company expects Phase II clinical data in 2024 and is preparing for a potential launch in 2025. Proceeds from its recent financing will also be used to advance additional pipeline candidates targeting infectious diseases such as CMV and immuno-oncology targets, and to support a partnership with Ono Pharmaceutical. Memo Therapeutics develops antibody discovery and immune repertoire analysis technologies that capture whole B-cell repertoires from any donor species and screen them in single-cell format to identify functional monoclonal antibodies. Its platform uses microfluidic single-cell molecular cloning and screening to assess millions of candidate antibodies and generate recombinant clonal cell lines expressing desired mAbs. The company’s pipeline focuses on infectious diseases and immuno‑oncology, with lead programs MTX-005 (a neutralizing antibody targeting BK virus) and COVAB 36 (an inhaled monoclonal antibody for SARS-CoV-2). Memo plans to use the new funding to advance MTX-005 into Phase 2 clinical development, expand its antibody pipeline, and secure new partnering agreements. The company also lists programs in cytomegalovirus (CMV) and Nipah virus, and says the recent funding together with a Swiss Federal COVID-19 grant will enable advancement of MTX-005 and COVAB 36 into clinical development this year. Memo Therapeutics is a private company based in Bio‑Technopark Zurich, Switzerland. Memo Therapeutics uses a droplet microfluidics-based single-cell platform (Dropzylla®) to capture and preserve entire B-cell repertoires and screen millions of candidate antibodies in functional assays. The platform generates recombinant clonal cell lines expressing monoclonal antibodies and is applied across species and indications for proprietary and partnered projects. The company’s pipeline includes programs in infectious diseases and immuno-oncology; its lead COVID-19 program is COVAB 36, a potent, fully-human monoclonal antibody that can be administered via inhalation. Memo received CHF 10.5 million from the Swiss Federal Funding Programme for COVID-19 Medicines to clinically develop COVAB 36, with the programme implemented by the Swiss Federal Office of Public Health and supported by Innosuisse. Memo completed preclinical development and plans to start phase 1 clinical studies with COVAB 36 in Q1 2022, and the project includes rapid development of a combination antibody partner for emerging variants via an ultra-fast update process. The company is a private firm located in Bio‑Technopark Zurich and was ranked in the TOP 100 Swiss Startups list from 2015 to 2017. Memo Therapeutics AG develops antibody discovery and immune repertoire analysis technologies built on microfluidic single-cell molecular cloning and screening. Its platform captures and preserves entire B-cell repertoires and screens them in single-cell format, assessing millions of candidate antibodies directly in functional assays to produce recombinant clonal cell lines expressing monoclonal antibodies with desired functions. The company’s pipeline includes infectious disease and immuno-oncology programs, with lead assets MTX-COVAB for COVID-19 and MTX-005 for BK virus in renal transplant patients. Memo says MTX-COVAB is a fully human, highly potent antibody that neutralizes all major known mutants and that it has agreed a fast-track development plan with regulators, planning to begin clinical studies in 2021. The CHF 14 million Series B financing will primarily fund advancement of MTX-COVAB through Phase II and GMP production, Phase II development of MTX-005, and expansion of additional anti-infectious candidates and partnering activities. The company is located in Bio-Technopark Zurich, Schlieren, Switzerland.

Total raised

$124M

Funding rounds

7

Latest round

Series C

Latest activity

May 2024